There are several steps involved in conducting experimental studies. If you were conducting an experimental study on the effects of a new drug that was created to reduce skin cancer, what type of design would you use, and why? Where would you begin, and how would you analyze the data?
Expert Solution Preview
Conducting an experimental study is a complex process that requires careful planning and execution. The aim of this study is to determine the type of design that would be appropriate for testing the effects of a new drug that was created to reduce skin cancer. Moreover, this answer will also explain where to begin and how to analyze the data.
For testing the effects of a new drug for reducing skin cancer, a randomized controlled trial design would be the most appropriate. In this type of study, two groups would be created randomly, and one group would be given the new drug, while the other group would be given a placebo. The efficacy of the drug would be determined by comparing the incidence of skin cancer in the two groups over a specified period.
The first step in conducting this study would involve identifying a suitable sample size and recruiting patients for the study. Researchers would then administer the new drug to one group of patients while giving the placebo to the other group. To ensure that the results are valid and reliable, researchers will need to avoid bias during the study, for example, by keeping the patients blinded to the treatment they are receiving.
After the study is complete, the data would be analyzed using statistical tests such as t-tests or ANOVA. These tests will help determine whether the drug has significant efficacy in reducing the incidence of skin cancer among patients.
In conclusion, conducting an experimental study requires careful planning and execution. For a study aimed at testing the effects of a new drug for reducing skin cancer, a randomized controlled trial design would be appropriate. The data would then be analyzed using statistical tests such as t-tests or ANOVA to determine the drug’s efficacy in reducing skin cancer incidence among patients.